AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, April 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2007 on Monday, April 16, 2007 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call. On the same date premarket, Amylin will release financial results for the first quarter of 2007. The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com/ approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 362-4832 (domestic) or (617) 597-5364 (international), passcode 71295475. A replay of the call will also be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 81236977. About Amylin Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1600 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/

Copyright